Our performance continues to be driven by robust sales of our innovative oncology products which have helped nearly double our revenues in a three-year time period.

237

Our solid first-quarter performance is in line with our expectations for the quarter and demonstrates progress towards achieving our financial goals for the year. We continue to remain focused on preparing for potential new product launches in 2003.

193

Investors have been very patient with the biotech industry, which has been one of the biggest money-losing industries in the history of mankind. The cumulative loss by this industry from its inception in 1976 is nearing $100 billion.

150

With the potential to launch as many as six new products or new indications for existing products in 2003, dependent on clinical success and regulatory approval, we are very well positioned to continue to deliver strong results.

149